Evidence map›Paper›PMID 33135478›Full record

ArticleAmerican journal of physiology. Renal physiology2020

Inhibition of 15-PGDH prevents ischemic renal injury by the PGE

Hye Jung Kim, Sun-Hee Kim, Minjung Kim, HyungJoo Baik, Seok Ju Park, Mi Seon Kang, Dong-Hyun Kim, Byeong Woo Kim, Sanford D Markowitz, Ki Beom Bae

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Renal physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Inhibiting 15-PGDH blocks blood-brain barrier deterioration and protects mice from Alzheimer's disease and traumatic brain injury.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  8. Prostaglandin EEXCLI journal · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Hye Jung KimDepartment of Surgery, Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.
Sun-Hee KimDepartment of Surgery, Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.
Minjung KimDepartment of Surgery, Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.
HyungJoo BaikDepartment of Surgery, Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.
Seok Ju ParkPaik Institute for Clinical Research, Inje University College of Medicine, Busan, Republic of Korea.
Mi Seon KangDepartment of Pathology, Inje University College of Medicine, Busan, Republic of Korea.
Dong-Hyun KimDepartment of Pharmacology, Inje University College of Medicine, Busan, Republic of Korea.
Byeong Woo KimDepartment of Nephrology, Haeundae Bumin Hospital, Busan, Republic of Korea.
Sanford D MarkowitzDepartment of Medicine, Case Western Reserve University, and Seidman Cancer Center, University Hospitals, Cleveland, Ohio.
Ki Beom BaeDepartment of Surgery, Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.
Inje University Busan Paik Hospital · KRInje University · KRBumin Hospital Group · KRUniversity Hospitals Seidman Cancer Center · US

Funding

Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and TreatmentR35CA197442 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARKOWITZ, SANFORD D. · 2017 to 2023
$6.6M
National Cancer Institute (NCI) NIH R35CA197442NCI NIH HHS R35 CA197442
6 · The paper itself

Abstract

In the present study, we demonstrated the marked activity of SW033291, an inhibitor of 15-hydoxyprostaglandin dehydrogenase (15-PGDH), in preventing acute kidney injury (AKI) in a murine model of ischemia-reperfusion injury. AKI due to ischemic injury represents a significant clinical problem. PGE

Indexed as

Acute Kidney InjuryAdenosineAnimalsBlood Flow VelocityDinoprostoneDisease Models, AnimalEnzyme InhibitorsHydroxyprostaglandin DehydrogenasesKidneyMaleMice, Inbred C57BLPyridinesReceptor, Adenosine A2AReceptors, Prostaglandin E, EP4 SubtypeRenal CirculationReperfusion Injury15-hydroxyprostaglandin dehydrogenaseAdenosineAdora2a protein, mouseDinoprostoneEnzyme InhibitorsHydroxyprostaglandin DehydrogenasesPtger4 protein, mousePyridinesReceptor, Adenosine A2AReceptors, Prostaglandin E, EP4 SubtypeSW033291Thiophenes15-hydoxyprostaglandin dehydrogenaseacute kidney injuryadenosineprostaglandin E2vasodilation

Identifiers

PMID33135478
PMCPMC7792690
OpenAlexW3097733802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.